Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pain, Migraine Clear all
Completed No phase listed Observational

The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)

NCT01004835
View directory record Official record
Conditions
Migraine Disease
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
10 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781
View directory record Official record
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 11, 2026, 8:16 AM EDT
Terminated Phase 4 Interventional Results available

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

NCT01629329
View directory record Official record
Conditions
Migraine Headaches
Interventions
Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 11, 2026, 8:16 AM EDT
Terminated No phase listed Observational

Treximet Migraine Brain Imaging Research Study

NCT01112553
View directory record Official record
Conditions
Acute Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Therapy for RefrACTORy Migraine Study

NCT02518464
View directory record Official record
Conditions
Migraine, Headache, Migraine Headache
Interventions
Ticagrelor 90 mg twice per day
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

NCT00109083
View directory record Official record
Conditions
Migraine Headaches
Interventions
RWJ-333369
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
25
States / cities
Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 11, 2026, 8:16 AM EDT
Not yet recruiting Not applicable Interventional

Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain

NCT07513662
View directory record Official record
Conditions
Migraine, Migraine in Adolescence
Interventions
BREATHE with Headache (BREATHE-HA), Enhanced Standard-of-Care: Headache Education
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 11, 2026, 8:16 AM EDT
Terminated No phase listed Observational

A Quality of Life Study in Patients With Migraines

NCT00298805
View directory record Official record
Conditions
Migraine, Headache, Depression
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 11, 2026, 8:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

NCT03432286
View directory record Official record
Conditions
Episodic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 11, 2026, 8:16 AM EDT
Recruiting No phase listed Observational

EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine

NCT07652034
View directory record Official record
Conditions
Migraine Disorders, Chronic Migraine Headache, Migraine
Interventions
Middle Meningeal Artery Embolization
Procedure
Lead sponsor
Cortex Neurovascular
Industry
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

NCT05518123
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Sherman Oaks, California • Stamford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 11, 2026, 8:16 AM EDT
Terminated Not applicable Interventional Results available

A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

NCT05730556
View directory record Official record
Conditions
Chronic Migraine
Interventions
Nerivio ®, Sham
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine

NCT01709708
View directory record Official record
Conditions
Chronic Migraine
Interventions
Marcaine, Saline
Drug
Lead sponsor
Tian Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
View directory record Official record
Conditions
Episodic Migraine
Interventions
Dextromethorphan and quinidine, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 11, 2026, 8:16 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine

NCT01228552
View directory record Official record
Conditions
Migraine Disorders, Migraine Headache, Migraine, Acute Migraine
Interventions
Topical, intra-oral ketoprofen gel, Placebo gel
Drug · Other
Lead sponsor
Behar, Caren, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 11, 2026, 8:16 AM EDT
Not listed No phase listed Observational

Open Label, 6-month Study for High Frequency and Chronic Migraine,

NCT06133491
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Daxibotulinumtonix A
Biological
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 11, 2026, 8:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Headache Ear Auditory Dizziness Sinus (HEADS) Registry

NCT07754266
View directory record Official record
Conditions
Headache Disorders, Dizziness, Vestibular Diseases, Sinus Disease, Vestibular Disorder, Migraine Disorders, Headache, Migraine, Facial Pain
Interventions
Not listed
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
North Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 11, 2026, 8:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-drug Interventions for Migraines

NCT01545466
View directory record Official record
Conditions
Migraine, Headache
Interventions
Mindfulness Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 11, 2026, 8:16 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 11, 2026, 8:16 AM EDT
Not listed Not applicable Interventional

Effects of a Multispecies Probiotic on Migraine

NCT04696458
View directory record Official record
Conditions
Migraine, Irritable Bowel Syndrome, Headache, Migraine
Interventions
Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo
Dietary Supplement · Other
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 11, 2026, 8:16 AM EDT
Recruiting Phase 2 Interventional

Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment

NCT07361549
View directory record Official record
Conditions
Refractory Migraine, Headache
Interventions
Lidocaine (drug), Saline
Drug
Lead sponsor
Daniel A Tonetti, MD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 11, 2026, 8:16 AM EDT